Skip to main content
NewslettersWatchlist

Oncolytics Biotech Inc(ONCY-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time

New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review

PR Newswire - Fri Oct 13, 2023

FN Media Group Presents USA News Group News Commentary

VANCOUVER, BC, Oct. 13, 2023 /PRNewswire/ -- USA News Group  -  Since September 2022, the US Food and Drug Administration (FDA) has seen new treatments for pancreatic cancer that are worthy of further investigation or approval. Known as one of the deadliest cancers on earth, analysis published in The Lancet in April 2023 showed a rising incidence of pancreatic cancer among individuals younger than 55 years, further demonstrating a need for more treatments. Among the treatments in development that caught the eye of the FDA over the past year are those that have come from  Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Pyxis Oncology, Inc. (NASDAQ: PYXS), AstraZeneca PLC (NASDAQ: AZN), Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS).

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe

market news
Premarket: TSX futures indicate upbeat open as metal prices gain
Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., April 26, 2024. REUTERS/Brendan McDermid
market news
The close: Major North American indexes rise as megacap tech stocks rally
A trader works on the floor at the New York Stock Exchange (NYSE) on April 25.
advisor etfs
Why this money manager is venturing back into emerging markets and adding more U.S. tech
Illustration of Andrew Pyle for The Mover. Nov. 5, 2022. Illustration by Joel Kimmel
globe investor
How a Canadian pirate-clad pastor helped ignite Trump Media’s market frenzy
Former President Donald Trump sits in Manhattan Criminal Court in New York, Thursday, April 25.
report on business
Activist investor targets Dye & Durham’s ‘underperformance and strategic missteps’ in letter to shareholders
Dye & Durham Ltd. says it has launched a strategic review of its non-core assets in an effort to reduce its debt. The logo for Dye & Durham Ltd. is shown in this undated handout photo. THE CANADIAN PRESS/HO
market news
The close: U.S. stocks fall as GDP report spreads rate-cut gloom; Alphabet surges 15% in post market
Traders work on the floor of the New York Stock Exchange shortly after the opening bell, Wednesday, April 24.
report on business
Fiera Capital’s largest shareholder looks to sell stake in company
Jean-Guy Desjardins, global CEO and founder of Fire Capital posses for a portrait at Fiera Capital, in Montreal on Monday, January 8, 2024. Evan Buhler/The Globe and Mail�
market news
The close: S&P 500 higher as markets weigh rising bond yields and upbeat U.S. earnings; TSX lower as rails slide
The Art Deco facade of the original Toronto Stock Exchange building is seen on Bay Street in Toronto in January of 2019.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).